Principle Research Solutions
Principle Research Solutions
  • Home
  • Current Studies
  • Mission
  • Services
  • More
    • Home
    • Current Studies
    • Mission
    • Services

  • Home
  • Current Studies
  • Mission
  • Services

Q32BIO  ADX-914-202         This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atopic Dermatitis. 

Sign Up/ Request info

Q32 BIO Atopic dermatitis

Participation Information

Volunteers needed for up to a 28 week long clinical trial with up to 13 office visits for an investigational product.  $100.00 stipend available for each office visit completed.  


To Qualify, you must meet the following INCLUSION CRITERIA:

1.)  18+ years of age

2.)  Have MODERATE to SEVERE eczema (atopic dermatitis)

3.)  Minimum of 10% eczema affected body surface area 


To Qualify, you must NOT meet the following EXCLUSION CRITERIA:

1.)  Weight over 264 lbs at your 1st office visit. 

2.)  Unwilling to discontinue current atopic dermatitis treatments

3.)  Female who is pregnant or breastfeeding



ClinicalTrials.gov Identifier:  NCT  05509023

https://clinicaltrials.gov/ct2/show/NCT05509023?term=q32+bio&draw=2&rank=1


q32 bio logo for ADX-914-202 trial

q32 bio logo for ADX-914-202 trial 

Contact Us

Drop us a line!

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Better yet, see us in person!

We love our patients, so feel free to visit during normal business hours.

Principle Research Solutions,llc

510 S Cowley Spokane, WA 99202

(509) 474-1107 MD@principleresearchsolutions.com

Hours

Mon

09:00 am – 05:00 pm

Tue

09:00 am – 05:00 pm

Wed

09:00 am – 05:00 pm

Thu

09:00 am – 05:00 pm

Fri

09:00 am – 05:00 pm

Sat

Closed

Sun

Closed

Photo Gallery

    Copyright © 2025 Principle Research Solutions,llc - All Rights Reserved.


    Powered by

    This website uses cookies.

    We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

    Accept